VCs dump $67.5M into Rempex (rump Mpex) for ESKAPE efflux pump inhibitors
This article was originally published in Scrip
Executive Summary
Rempex Pharmaceuticals, a San Diego, California-based company in its second round of venture funding, has raised $67.5 million to advance new treatments for resistant Gram-negative infections, based on technology originally developed by Mpex Pharmaceuticals. Frazier Healthcare Ventures and Vivo Ventures joined existing investors SV Life Sciences, OrbiMed Advisors and Adams Street Partners on the round.